Reaction
Herpes Zoster Infection Neurological reporting signals
As of the last recalculation, Herpes Zoster Infection Neurological appears in 159 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 215.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canakinumab | 16 | 215.1 | 215.5 |
| Alemtuzumab | 24 | 191.1 | 191.4 |
| Busulfan | 20 | 190.2 | 190.4 |
| Anakinra | 19 | 170.1 | 170.3 |
| Indomethacin | 14 | 151.6 | 151.7 |
| Baricitinib | 7 | 99.4 | 99.4 |
| Tofacitinib Citrate | 9 | 95.2 | 95.3 |
| Fludarabine Phosphate | 20 | 76.0 | 76.1 |